title: Production and tumour uptake of [64Cu]Pyruvaldehyde-bis (N4-methylthiosemicarbazone) for PET and/or therapeutic purposes.
abstract: BACKGROUND
  Copper-64 (T(1/2)=12.7 degrees h) is an important radionuclide used both in PET imaging and therapy. [(64)Cu]-pyruvaldehyde- bis(N(4)-methylthiosemicarbazone) ([64Cu]-PTSM) has already been used in the detection of cerebral and myocardial blood flow. In this study, a simple production method and tumor accumulation of [(64)Cu]-PTSM in fibrosarcoma-bearing mice were reported.
  
  
  METHODS
  Cu-64 was produced via the 68Zn(p, alpha n)(64)Cu nuclear reaction. [(64)Cu]-PTSM was prepared using in-house made PTSM ligand and [(64)Cu]cuprous acetate and injected to fibrosarcoma-bearing mice.
  
  
  RESULTS
  Copper-64 was prepared in chloride form ( approximately 200 mCi, > 95% chemical yield at 180 degrees microA for 1.1 h irradiation, radionuclidic purity > 96%, copper-67 as impurity). The solution of (64)Cu- PTSM was prepared in > 80% radiochemical yield and more than 98% radiochemical purity. A significant tumor uptake was observed 2 hours post injection in tumor-bearing mice (tumor/muscle: 9, tumor/blood: 6).
  
  
  CONCLUSIONS
  [(64)Cu]-PTSM was prepared on a radiopharmaceutical scale using readily available zinc-68, with high quality and was shown to possess application in the therapy and/or imaging of fibrosarcoma.
authors: Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Karaj, Iran. ajalilian@nrcam.org
authors: Amir Reza
authors: AR
authors: Jalilian
authors: Pejman
authors: P
authors: Rowshanfarzad
authors: Yousef Yari
authors: YY
authors: Kamrani
authors: Kamaleddin
authors: K
authors: Shafaii
authors: Mohammad
authors: M
authors: Mirzaii
mesh_terms: D000818:Animals; D003301:Copper Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use; D004355:Drug Stability; D051379:Mice; D008807:Mice, Inbred BALB C; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012513:Sarcoma, Experimental / Q000000981:diagnostic imaging / Q000532:radiotherapy; D013882:Thiosemicarbazones / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014018:Tissue Distribution
chemical_list: D003301:Copper Radioisotopes; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D013882:Thiosemicarbazones; C063293:copper (II) pyruvaldehyde bis(N(4)-dimethylthiosemicarbazone)